Shockwave Medical Inc (SWAV)
330.04
-0.84
(-0.25%)
USD |
NASDAQ |
May 17, 16:00
330.04
0.00 (0.00%)
After-Hours: 20:00
Shockwave Medical SG&A Expense (TTM): 360.61M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 360.61M |
| December 31, 2023 | 330.10M |
| September 30, 2023 | 298.42M |
| June 30, 2023 | 276.58M |
| March 31, 2023 | 243.79M |
| December 31, 2022 | 218.92M |
| September 30, 2022 | 201.37M |
| June 30, 2022 | 182.51M |
| March 31, 2022 | 163.17M |
| December 31, 2021 | 146.04M |
| September 30, 2021 | 126.28M |
| Date | Value |
|---|---|
| June 30, 2021 | 107.85M |
| March 31, 2021 | 90.12M |
| December 31, 2020 | 75.54M |
| September 30, 2020 | 66.52M |
| June 30, 2020 | 58.92M |
| March 31, 2020 | 52.52M |
| December 31, 2019 | 44.75M |
| September 30, 2019 | 37.47M |
| June 30, 2019 | 32.02M |
| March 31, 2019 | 27.57M |
| December 31, 2018 | 23.52M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
32.02M
Minimum
Jun 2019
360.61M
Maximum
Mar 2024
155.67M
Average
136.16M
Median
SG&A Expense (TTM) Benchmarks
| Boston Scientific Corp | 5.339B |
| Masimo Corp | 627.60M |
| Tactile Systems Technology Inc | 171.08M |
| RxSight Inc | 81.87M |
| Perspective Therapeutics Inc | 19.11M |